Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: p.G12C-mutated pancreatic cancer are unknown. METHODS: p.G12C-mutated pancreatic cancer who had received at least one previous systemic therapy. The primary objective of phase 1 was to assess safety and to identify the recommended dose for phase 2. In phase 2, patients received sotorasib at a dose of 960 mg orally once daily. The primary end point for phase 2 was a centrally confirmed objective response (defined as a complete or partial response). Efficacy end points were assessed in the pooled population from both phases and included objective response, duration of response, time to objective response, disease control (defined as an objective response or stable disease), progression-free survival, and overall survival. Safety was also assessed. RESULTS: The pooled population from phases 1 and 2 consisted of 38 patients, all of whom had metastatic disease at enrollment and had previously received chemotherapy. At baseline, patients had received a median of 2 lines (range, 1 to 8) of therapy previously. All 38 patients received sotorasib in the trial. A total of 8 patients had a centrally confirmed objective response (21%; 95% confidence interval [CI], 10 to 37). The median progression-free survival was 4.0 months (95% CI, 2.8 to 5.6), and the median overall survival was 6.9 months (95% CI, 5.0 to 9.1). Treatment-related adverse events of any grade were reported in 16 patients (42%); 6 patients (16%) had grade 3 adverse events. No treatment-related adverse events were fatal or led to treatment discontinuation. CONCLUSIONS: p.G12C-mutated advanced pancreatic cancer who had received previous treatment. (Funded by Amgen and others; CodeBreaK 100 ClinicalTrials.gov number, NCT03600883.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CodeBreaK100 (NCT03600883) clinical trial evaluated the safety and efficacy of sotorasib in advanced KRASG12C-mutant cancers, including 38 patients with metastatic, previously chemotherapy-treated PDAC. In these patients, a 21% objective response rate (ORR), a median progression-free survival (PFS) of 4.0 months, and a median overall survival (OS) of 6.9 months were observed (26).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [26]
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [16]
In the citing paper
“In the first published clinical series of KRASG12C inhibitor monotherapy in advanced PDAC, responses occurred in a minority of patients (~21%) and were generally transient75.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [75]
In the citing paper
“Even with recent advances in this space, currently only inhibitors targeting a specific KRAS mutation (KRAS G12C) have been FDA-approved in NSCLC (2–5).”
From Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors (2024) · cites this paper as [5]
In the citing paper
“Although recently developed KRAS G12C inhibitors, 10 including sotorasib and adagrasib, have shown antitumor activity in patients with previously treated KRAS G12C-mutated cancer, the extent of the clinical benefit remains limited, and better therapies to target KRAS G12C remain a high priority.[11][12][13][14][15][16][17][18]”
From Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation (2023) · cites this paper as [15]
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824
Self-citationK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationDoebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30691-6 · Cited by 1,790
Self-citation
Cited by
Items 301–400 of 579
Capurso, G., Garajová, I., Neuzillet, C., Leta, L. C., Dusetti, N., & Reni, M. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.020 · Cited by 4
Epigenetic Regulators as Therapeutic Targets in Pancreatic Ductal Adenocarcinoma
Kubiak, K., & Inkielewicz‐Stępniak, I. (2026) · Cancers · doi:10.3390/cancers18061001 · Cited by 4
Takrori, E., Abdulmajid, M., Devagudi, D., Sohail, R., Sadiq, Z., Berneau, C., Shenouda, A., Adelli, R., Peshin, S., & Singal, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104413 · Cited by 3
High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer
Sridalla, K., Machhi, J. K., Vitello, D. J., Chibucos, A., Cox, M. C., Wells, A., Horowitz, A., Rengaraju, V., Shen, C., Romero, N., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-0609 · Cited by 3
Targeting KRAS for cancer therapy
Jia, J., Liu, R., Adamide, T. A., Fernandez, I. E., & Stathopoulos, G. T. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70546 · Cited by 4
Conroy, T., & Ducreux, M. P. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.08.003 · Cited by 3
Dong, S., Agarunov, E., Fasullo, M., Kim, K., Khanna, L. G., Haber, G. B., Janec, E. M., Simeone, D. M., Oberstein, P. E., & Gonda, T. A. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002786 · Cited by 3
Nanoparticles Bounded to Interfering RNAs as a Therapy for Pancreatic Cancer: A Systematic Review
Lara, P., Quiñonero, F., Ortíz, R., Prados, J. C., & Melguizo, C. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.2013 · Cited by 4
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Doleschal, B. (2024) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-024-01003-6 · Cited by 5
Hepatobiliary Adverse Events Associated With the KRAS p.G12C Inhibitor Sotorasib
Frey, C. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70104 · Cited by 3
Megid, R., Ribeiro, G., Gomes, I. N. F., Laus, A. C., Leal, L. F., da Silva, L. S., Ariwoola, A.-B. A., Dias, J. M., Reis, R. M., & Oliveira, R. J. D. S. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1537523 · Cited by 3
Current status of cancer genome medicine for pancreatic ductal adenocarcinoma
Doi, T., Ishikawa, T., Moriguchi, M., & Itoh, Y. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf012 · Cited by 4
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
Demir, T., Moloney, C., & Mahalingam, D. (2025) · Cancers · doi:10.3390/cancers17050715 · Cited by 4
Vornhülz, M., Angelberger, M., Sirtl, S., Philipp, A. B., Rössler, D. C., Ondrejkova, K., Markwardt, D., Heinrich, K., Westphalen, C. B., Heinemann, V., et al. (2025) · Oncology Research and Treatment · doi:10.1159/000545975 · Cited by 3
Molecular diagnostics in clinical oncology: an overview
Имянитов, Е. Н., & Соколенко, А. П. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001346 · Cited by 4
RASH3D19 mediates RAS activation through a positive feedback loop in KRAS-mutant cancer
Treekitkarnmongkol, W., Katayama, H., Sankaran, D., Tai, M.-C., Rauth, S., Chen, H., Nguyen, T., Hara, K., Thege, F. I., Ponnusamy, M. P., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01816-5 · Cited by 3
Miyan, J., Vudatha, V., Cao, L., Zhang, P., Zheng, G., Zheng, L., Trevino, J., Zhou, D., & Khan, S. (2026) · Cancers · doi:10.3390/cancers18060920 · Cited by 3
Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer
Elhariri, A., Patel, J., Mahadevia, H. J., Albelal, D., Ahmed, A., Jones, J. C., Borad, M. J., & Babiker, H. M. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01088-3 · Cited by 3
Liu, H., Qiang, M., Zhang, Y., Wang, H., Xing, Y., & Guo, R. (2024) · Medicine · doi:10.1097/md.0000000000039334 · Cited by 4
Factors associated with actionable gene aberrations in pancreatic cancer based on the C-CAT database
Endo, G., Ishigaki, K., Nakai, Y., Nishio, H., Fukuda, K., Ishida, K., Takaoka, S., Tokito, Y., Fukuda, R., Noguchi, K., et al. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02253-9 · Cited by 3
Resell, M., Graarud, E. P., Rabben, H.-L., Sharma, A., Hagen, L., Hoang, L., Skogaker, N. T., Aarvik, A., Svensson, M. K., Amrutkar, M., et al. (2025) · Proteomes · doi:10.3390/proteomes13020020 · Cited by 4
Hikita, E., Gando, Y., Chubachi, H., Shirota, M., Kushiyama, A., & Yasu, T. (2023) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2023.01043 · Cited by 3
Significance of Tumor Microenvironment for Regulating Pancreatic Cancer
Ijichi, H. (2023) · Cancers · doi:10.3390/cancers15092482 · Cited by 3
Targeting Hyperactive Ras Signaling in Pediatric Cancer
Levinson, A. L., Shannon, K., & Huang, B. J. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041572 · Cited by 3
Precision Oncology in Pancreatic Cancer and Future Treatment Directions
Mahmasani, L. A., & O'Reilly, E. M. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.03.002 · Cited by 3
Jesenko, T., Omerzel, M., Zivic, T., Serša, G., & Čemažar, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157165 · Cited by 2
Serala, K., Mdletshe, S., Bai, J., Abrahams, A., Gayet, O., Moubri, L., Dusetti, N., & Prince, S. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70736 · Cited by 2
Targeting Advanced Pancreatic Ductal Adenocarcinoma: A Practical Overview
Citterio, C., Vecchia, S., Mordenti, P., Anselmi, E., Ratti, M., Guasconi, M., & Orlandi, E. (2025) · Gastroenterology Insights · doi:10.3390/gastroent16030026 · Cited by 2
Defazio, G., Scolari, F., Fancelli, S., Polvani, S., Lavacchi, D., Picariello, L., Tubita, A., Luconi, M., Antonuzzo, L., Galli, A., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1613773 · Cited by 2
TP53 and KRAS co-mutations are associated with worse outcomes in mucinous ovarian carcinomas
Zhang, Y., Barkdull, S., Kontoyiannis, P. D., Legarreta, A. F., Gershenson, D. M., Ramalingam, P., Frumovitz, M. M., & Sood, A. K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1573801 · Cited by 4
Driving Precision Medicine in Pancreatic Cancer With Molecular Genetics
Farooq, M., & Pishvaian, M. J. (2025) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2025.08.004 · Cited by 2
Emerging Systemic Therapy Considerations for Pancreatic Cancer
Liang, K.-L., Guo, M. Z., & Zaidi, N. (2025) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2025.07.006 · Cited by 2
Xie, C., Ke, J., & Liu, F. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.12.008 · Cited by 3
Ripolli, A., Niccolò, N., Kauffmann, E. F., Ginesini, M., Viti, V., Lombardo, C., Vasile, E., Carla, C., Amorese, G., & Boggi, U. (2026) · Updates in Surgery · doi:10.1007/s13304-025-02502-9 · Cited by 2
Joung, R. H., & Snyder, R. A. (2026) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-26-515560 · Cited by 3
Finding More in Less: Precision Medicine for Pancreatic Cancer Using Residual Cytology Samples
Antón‐Peñalver, R., Ortega, M., González, J., Compañ, D., Galindo, C. G., Arnau, C., Huerta, M., Gambardella, V., Roda, D., Villagrasa, R., et al. (2026) · Cytopathology · doi:10.1111/cyt.70055 · Cited by 2
Yang, Z., Theardy, M. S., Chen, S., Wei, Y., Takeda, M., Zeng, Y., Wang, X., Yao, J., Li, J., Thirasastr, P., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102613 · Cited by 2
The Development of Novel Treatment Strategies for Rhabdomyosarcoma
Nakano, K. (2026) · Cancers · doi:10.3390/cancers18040690 · Cited by 2
Advancing precision medicine in pancreatic cancer using novel biomarkers and clinical targets
Murthy, D., Seyhan, A. A., den Hollander, P., Lu, S., Kuburich, N. A., Gould, C., Karam, A., Sun, K., Schupp, P. G., Safran, H., et al. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101476 · Cited by 3
Zhu, Y., Ma, K., Hao, Q., Fu, K., Hei, F., Ning, S., Yin, Z., Guo, W., Zou, H., & Tan, Z. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02667-w · Cited by 2
Current advances in immunotherapy for KRAS-Mutant pancreatic cancer
Li, M. Y., Wang, X., Li, P., Gong, H., Wu, J., & Mao, Y. (2026) · Clinical and Experimental Medicine · doi:10.1007/s10238-026-02201-8 · Cited by 2
Research progress on the etiology and pathogenesis of pancreatic cancer: a narrative review
Guo, M., Han, Q., Wang, Z., Ya, D., & Wang, X. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1781024 · Cited by 2
Xue, S., Xu, H., Ma, J., Wang, Y., Lu, W., Cui, J., & Wang, L. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218684 · Cited by 2
Kim, B., & Lee, J. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135682 · Cited by 2
KRAS inhibition is an effective therapy for appendiceal adenocarcinoma
Chowdhury, S., Ito, I., Pattalachinti, V. K., Yousef, A. M. G., Yousef, M., Khoury, S. E., Hornstein, N. J., Seldomridge, A. N., Hong, D. S., Overman, M. J., et al. (2026) · Journal of Hematology & Oncology · doi:10.1186/s13045-026-01817-3 · Cited by 3
Self-citationPrecision Medicine in Pancreatic Cancer: Targeting KRAS and Beyond
Schürmann, H., Park, W., O'Kane, G. M., Sciortino, C., Niger, M., Reichert, M., Olive, K. P., Pretzell, I., & Westphalen, C. B. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01236-x · Cited by 3
Aguilar‐Valdés, A., González‐Vela, F., Sánchez‐Vidal, H., & Martínez‐Aguilar, J. (2023) · PROTEOMICS · doi:10.1002/pmic.202300041 · Cited by 2
Balta, K. Y., Welch, S., Vincent, M. D., & Breadner, D. A. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-190 · Cited by 2
Self-citationDong, B., Zhang, Y., Gao, H., Liu, J., & Li, J. (2024) · Biochemical Genetics · doi:10.1007/s10528-023-10625-0 · Cited by 2
Eid, M., Trizuljak, J., Taslerová, R., Gryc, M., Vlažný, J., Vilmanova, S., Jelinkova, M., Homolová, A., Tuček, Š., Hlavsa, J., et al. (2024) · Mutagenesis · doi:10.1093/mutage/geae014 · Cited by 2
Role of molecular biology in the management of pancreatic cancer
Boilève, A., Smolenschi, C., Lambert, A., Boige, V., Tarabay, A., Valéry, M., Fuerea, A. C., Pudlarz, T., Conroy, T., Hollebecque, A., et al. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i7.2902 · Cited by 4
Self-citationKRAS combination strategies: How well aligned is clinical and preclinical research?
Nadal, E., Ambrogio, C., Santamaría, D., & Lindsay, C. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00018-8 · Cited by 2
Advances in Targeting KRAS G12C in Gastrointestinal Malignancies: Focus on KRAS G12C Inhibitors
Hoyek, C., Pirozzi, A., Jones, J. M., Rimassa, L., Sonbol, M. B., & Bekaii‐Saab, T. (2024) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2024.20.2.7 · Cited by 3
Hu, Z., & Martí, J. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109599 · Cited by 3
Hussung, S., Akhoundova, D., Pistoni, C., Lenggenhager, D. M., Töpfer, A., Pauli, C., Pestalozzi, B., Britschgi, C., Zoche, M., Rechsteiner, M., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100134 · Cited by 2
Shen, S., Zhang, Q., Wang, Y., Chen, H., Gong, S., Liu, Y., Gai, C., Chen, H., Zhu, E., Yang, B. H., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci185278 · Cited by 2
Hang, J., Dong, X., 武丽霞, Gong, L., Huang, J., Guo, J., Ma, M., Xiao, L., Chen, X., Che, X., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123631 · Cited by 2
Prognostic Properties of KRAS Gene Mutation Subtypes in Resected Pancreatic Ductal Adenocarcinoma
Nusrat, F., Gorgov, E., Khanna, A., Isesele, O., Bowne, W. B., Lavu, H., Yeo, C. J., Jiang, W., Jain, A., & Nevler, A. (2025) · Pancreas · doi:10.1097/mpa.0000000000002458 · Cited by 2
Zhang, A., & Chen, J. Y. (2025) · Intelligent Oncology · doi:10.1016/j.intonc.2025.06.004 · Cited by 2
Wang, Q., Lv, N., Xu, D., Wu, Y. F., Wu, J., Gao, W., Wei, J., Xiao, B., Tu, M., & Jiang, K. (2025) · BMC Cancer · doi:10.1186/s12885-025-14601-2 · Cited by 2
Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition
Zhang, Z., Liu, Y., Xu, Y., Xu, Z., Jia, J., Jin, Y., Wang, W., & Liu, L. (2024) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2023288 · Cited by 3
Glucose-6-phosphate dehydrogenase deficiency accelerates pancreatic acinar-to-ductal metaplasiaPreprint
Radyk, M. D., Nelson, B. S., Halbrook, C. J., Wood, A., Lavoie, B. L., Salvatore, L., Corfas, G., Colacino, J. A., Shah, Y. M., Crawford, H. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.06.565895 · Cited by 2
Identification of Phosphotyrosine-Mutant Desmin in Human Pancreatic CancerPreprint
Kendrick, N. C., Darie, C. C., Hoelter, M., Koll, A., & Johansen, J. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.14.618246 · Cited by 2
Pancreatic cancer patient-derived organoids capture therapy response and tumor evolutionPreprint
Gout, J., Perkhofer, L., Lindenmayer, J., Resheq, Y. J., Schwab, J. D., Kraus, J. M., Roger, É., Srinivasan, D., Zimmer, E., Mayer, B., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.24.650216 · Cited by 3
Moyana, T. N., & Merz, V. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1651566 · Cited by 3
PCNA Inhibition Enhances the Antitumor Activity of KRAS-Targeted Therapies in Pancreatic CancerPreprint
Bannoura, S. F., Khan, H. Y., Aboukameel, A., Wan, Y., Bao, B., Uddin, M. H., Jimenez, H., Aboukameel, A., Siddiqui, R., Khan, F., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.06.692635 · Cited by 4
Frost, M. G., Jensen, K. J., Jimenez‐Solem, E., Qvortrup, C., Kühlmann, T. P., Andersen, J. L., Høgdall, E. V. S., & Petersen, T. S. (2024) · Genes Chromosomes and Cancer · doi:10.1002/gcc.23236 · Cited by 1
Gupta, D., Gupta, D. S., & Shetty, S. R. (2024) · Springer eBooks · doi:10.1007/978-981-97-3001-8_9 · Cited by 1
Liu, Y., Li, Y., Li, G., Wang, A., & Chu, H. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110137 · Cited by 1
Tamayo, N. A., Wurz, R. P., & Lanman, B. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00001-2 · Cited by 1
Kim, B., Kim, J., Yang, S., Ahn, J., Jung, K., Lee, J.-C., & Hwang, J. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i2.100167 · Cited by 1
Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort
Hegenberg, S., Germing, T., Schlageter, E., Ekmekçiu, I., Christmann, J., Tannapfel, A., & Reinacher‐Schick, A. (2025) · Oncology Research and Treatment · doi:10.1159/000543997 · Cited by 1
Vigié, T., Perrier, A., Chanez, B., de Martino, J., Favre, L., Coulet, F., Bachet, J., Guillerm, E., & Mas, L. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241312078 · Cited by 1
Leitlinien in Kürze Updates - Pankreas
von Fritsch, L., Honselmann, K. C., & Keck, T. (2025) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-2529-5372 · Cited by 1
Okada, Y., Sato, Y., Shinomiya, R., Miyake, T., Takahashi, T., Yokoyama, R., Mitsui, Y., Tomonari, T., Okamoto, K., Sogabe, M., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02677-y · Cited by 1
Tsai, A. K., Rollins, M. R., Ellefson, M. A., Schmiechen, Z. C., Burrack, A. L., Hulbert, A., Qian, G., Zhang, H., Cruz-Hinojoza, E., Butler, J. Z., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1101/2025.06.04.657887 · Cited by 1
Elevated KRAS protein level is associated with better survival in pancreatic cancer
Stålberg, S. M., Silwal‐Pandit, L., Hamfjord, J., Nebdal, D. J. H., Lehtiö, J., Lingjærde, O. C., Skålhegg, B. S., & Kure, E. H. (2025) · BMC Cancer · doi:10.1186/s12885-025-14461-w · Cited by 1
Min, J., Oh, W., & Kim, B. (2025) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2025.05.27 · Cited by 1
Histopathological and genetic landscape of pancreatic ductal adenocarcinoma and its variants
Caldwell, N. J., & Zhang, M. L. (2025) · Seminars in Diagnostic Pathology · doi:10.1016/j.semdp.2025.150948 · Cited by 1
Tantawi, H. N., Mochirian, P., Truong, M., Beauregard, J., Collins, L., Kanaan, G. N., Komati, H., Leblanc, L., Maharsy, W. M., Manchoju, A., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00378 · Cited by 1
Jung, J., Hong, J. Y., Park, S. H., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., Lee, J., Ha, S. Y., Ahn, S., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251351438 · Cited by 2
Interventional management of pancreatic cancer: Current strategies and future horizons
Wang, Y., Yan, R., Lü, J., Guo, J., & Teng, G. (2025) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000097 · Cited by 1
Heads or tails? In-depth analysis of pancreatic cancer outcome according to tumor location
Fernandes, A., Lambert, A., Tarabay, A., Hollebecque, A., Smolenschi, C., Valéry, M., Pudlarz, T., Fuerea, A. C., Camilleri, G. M., Delaye, M., et al. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100245 · Cited by 2
Self-citationAslani, S., McKay, O., Lipton, L. R., Ganju, V., & Croagh, D. G. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1691760 · Cited by 1
Characteristics of KRAS WT pancreatic adenocarcinomas: results of a large French multicentric cohort
Trystram, N., Cros, J. F., Blons, H., Garinet, S., Nicolle, R., Corre, D. L., Zhao, S. L., Biagi, J. J., Harlé, A., Conroy, T., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251339939 · Cited by 1
Self-citationZhao, Y., Li, Y., Wang, S., & Wu, C. (2025) · Clinical Case Reports · doi:10.1002/ccr3.71505 · Cited by 1
Nazir, N., Husnain, M., Waqar, A., Kanwal, M., Aziz, T. A., Al‐Hoshani, N., Mohamed, R. A. E. H., Alwethaynani, M. S., Al‐Joufi, F. A., & Hassan, R. N. (2026) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416526500353 · Cited by 2
Aslani, S., LEE, B. T. O., Strickland, A., Shen, H., & Croagh, D. G. (2026) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2025.2610630 · Cited by 1
Kurogi, S., Tsukamoto, Y., Yamamura, J., Nakada, C., Uchida, T., Kamiyama, N., Nakamura, S., Hirashita, Y., Hirashita, T., Kobayashi, T., et al. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-0638 · Cited by 1
Wang, J., Xu, K., Xu, L., Geng, J., Liu, C., Gu, X., & Li, X. (2026) · Cancer Management and Research · doi:10.2147/cmar.s573143 · Cited by 1
Unravelling the pathogenesis and therapeutic approaches of pancreatic ductal adenocarcinoma
Roy, I., & Thakur, R. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04289-6 · Cited by 1
Studiale, V., Taravella, A., Landi, M., Antoniotti, C., Botticelli, A., Marchetti, P., & Cremolini, C. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103127 · Cited by 1
Liang, S., Li, Y., Wan, K., Zhang, W., & Xiong, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1775677 · Cited by 1
Massinissa, Y., Benhouda, A., Khadraoui, H., Benouda, D., Khettache, W., & Soussi, A. (2026) · African Health Sciences · doi:10.4314/ahs.v26i1.12 · Cited by 1
Artificial intelligence: Catalyzing a new era in pancreatic cancer cure
Wang, J., Luo, W., Zhang, M., Wang, Y., Ye, L., Qiu, J. U. N. T. A. O., Liu, Y., Weng, G., Liu, T., Cao, Z., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218558 · Cited by 1
Umemoto, K., Nakahara, K., Ohike, N., Satta, Y., Akihiro, S., Igarashi, Y., Nagata, Y., Kubota, Y., Takeda, H., Horie, Y., et al. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02447-9 · Cited by 1
Self-citationWhole genome sequencing in oesophageal adenocarcinoma unmasks potential precision therapies
Sharma, S., Wong, H. Y., Johnston, R. L., Koufariotis, L. T., Wood, S., Hollway, G. E., Aoude, L. G., Davidson, A. L., Pearson, J. V., Lin, F. P., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-16044-9 · Cited by 1
Zhu, C., Wang, C., Zhu, Y., Yu, Z., Lin, Y., Zhang, Y., Jin, Y., Zhang, N., Liu, X., Ye, X., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00836 · Cited by 1
Chen, Y., Zhang, J., Miao, Y., Wang, J., Na, J., Liu, X., Yi, Z., Chen, H., & Liu, M. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01553-4 · Cited by 1
RAS Inhibitors: Changing the Paradigm from the Undruggable
Campana, F., Bellis, E. D., Porcaro, F., Guida, G. D., Gravara, L. D., Servetto, A., Morgillo, F., Papaccio, F., Filippelli, A., Corte, C. M. D., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070773 · Cited by 1
Metadata
- Authors
- Strickler, J. H., Satake, H., George, T. J., Yaeger, R., Hollebecque, A., Garrido-Laguna, I., Schuler, M., Burns, T. F., Coveler, A. L., Falchook, G. S., Vincent, M., Sunakawa, Y., Dahan, L., Bajor, D., Rha, S.-Y., Lemech, C., Juric, D., Rehn, M., Ngarmchamnanrith, G., Jafarinasabian, P., Tran, Q., & Hong, D. S.
- Affiliations
- Kansai Medical University (JP)
- From Duke University Medical Center, Durham, NC (J.H.S.); Kansai Medical University, Shinmachi, Hirakata (H.S.), and St. Marianna University School of Medicine, Kawasaki (Y.S.) — both in Japan; University of Florida, Gainesville (T.J.G.); Memorial Sloan Kettering Cancer Center, New York (R.Y.); Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif (A.H.), and Marseille University Hospital, Marseille (L.D.) — both in France; Huntsman Cancer Institute, University of Utah, Salt Lake City (I.G.-L.); West German Cancer Center, University Hospital Essen, Essen (M.S.); University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh (T.F.B.); Fred Hutchinson Cancer Center, University of Washington, Seattle (A.L.C.); Sarah Cannon Research Institute at HealthONE, Denver (G.S.F.); London Regional Cancer Program, London, ON, Canada (M.V.); University Hospitals Cleveland Medical Center, Cleveland (D.B.); Yonsei Cancer Center, Seoul, South Korea (S.-Y.R.); Scientia Clinical Research and Prince of Wa...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-05
- Volume
- 388
- Issue
- 1
- Pages
- 33-43
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10506456
- OpenAlex
- W4312094134
- Semantic Scholar
- 488922b069e36918a499827187276c02b891cb58
- Cited by
- 527
- References
- 34
- Citations by year
- 2026: 138 · 2025: 169 · 2024: 142 · 2023: 78
- FWCI
- 40.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Amgen Inc.
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- sotorasib, KRAS G12C mutation, advanced pancreatic cancer, KRAS inhibitors, metastatic pancreatic cancer, previously treated patients, objective response, progression-free survival, overall survival, treatment safety, adverse events
- MeSH terms
- Immune Checkpoint Inhibitors, Administration, Oral, Humans, Lung Neoplasms, Mutation, Pancreatic Neoplasms, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.